Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye800 for Intraoperative Imaging in Lung Cancer
NCT06101394Phase 2Recruiting
- Sponsor
- University of Turin
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab-IRDye 800CW in non-small cell lung cancer (NSCLC), sponsored by University of Turin. Started Jan 2024; status: recruiting.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06101394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101394.